New Norovirus-Like Particles Available

To support norovirus research and development, The Native Antigen Company offers 6 new norovirus-like particles, produced from our proprietary VirtuE™ mammalian expression system.

Our Norovirus-Like Particles

Virus-like particles (VLPs) comprise the structural proteins of a viral particle, but don’t contain genomic material, making them non-infectious, while presenting all of the structural epitopes of a native virus. Because of these properties, VLPs have been extensively used in diagnostic and vaccine R&D over recent years.

To support norovirus research and development, The Native Antigen Company offers an extended range of 8 norovirus-like particles, produced from our proprietary VirtuE™ (HEK293) and insect-baculovirus expression systems.

Norovirus Electron Micrographs: negative stain EM of norovirus GI.1 VLPs produced by The Native Antigen Company, showing intact particles.

Our norovirus VLPs are comprised of VP1 proteins, that self-assemble as an icosahedron of 180 subunits. VP1 is a 59kDa glycoprotein with three key domains: The shell domain (S domain) contains elements essential for the formation of the icosahedron. The Protruding domain (P domain) is divided into sub-domains P1 and P2. The P domain interacts in dimeric contacts that increase the stability of the capsid and form the protrusions on the virion. A hypervariable region in P2 is thought to play an important role in receptor binding and immune reactivity.

Our VLPs are non-infectious and safe to use, while displaying native-like epitopes and glycosylation patterns. A study by Metz and colleagues, for example, showed that our VirtuE™-expressed dengue VLPs exhibit comparable epitopes to native viral particles. Our VLPs are suitable for a wide range of applications, including the development of in vitro diagnostic assays and vaccines. The highly repetitive structural patterns presented by VLPs also makes them ideal antigens for raising high-avidity antibodies.

For more information on each of our norovirus-like particles, click the buttons below or get in touch with a member of our team:

Norovirus GI.I VLP (Insect)

Norovirus GI.3 VLP (HEK293)

Norovirus GII.2 VLP (HEK293)

Norovirus GII.4 VLP (HEK293)

Norovirus GII.6 VLP (HEK293)

Norovirus GII.10 VLP (HEK293)

Norovirus GII.17 VLP (HEK293)

Norovirus GIX.1 VLP (HEK293)

Norovirus GII.3 VLP (Hu/GII.3/SW4/2012/TN)

See our Full Range

In addition to virus-like particles, we offer a range of genotype-specific primary antibodies:

See Our Full Range

Get in Touch

Name

Email Address

Who is your message for?

Message

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these Yes please, keep me up to date No thank you

10 + 3 =

The Native Antigen Company expands its range of Omicron antigens to include BA.5 variant

by Bobby Mitchell | 2nd November 2022 | COVID-19 | 0 Comments

New antigens support research into BA.5 variant, currently responsible for over half of global COVID-19 cases Oxford, UK, 02 November 2022: The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables...

The Role of Serology in Tracking COVID-19 Mutations

by James Shore | 27th August 2021 | COVID-19, Disease trends, Immunoassays, Research, Vaccines | 0 Comments

This article was originally published on Clinical Lab Products. As SARS-CoV-2 began its global proliferation in early 2020, scientists hastened to investigate its biology, develop diagnostic tests, and design candidate vaccines, marking one of the most...

Preparing for Disease Y: A Better Serological Toolbox

by James Shore | 26th July 2021 | COVID-19, Disease trends, Immunoassays, Neglected Tropical Diseases, Research, Vaccines | 0 Comments

This article was originally published on Clinical Lab Manager. It’s been over a year since the World Health Organization (WHO) declared COVID-19 a pandemic. SARS-CoV-2 has since infected 200 million people, resulting in nearly 4 million deaths and substantial economic...

Keeping Up with the New SARS-CoV-2 Variant Nomenclature

by James Shore | 3rd June 2021 | Coronaviruses, COVID-19, Disease trends | 0 Comments

If you’ve been struggling to make sense of SARS-CoV-2 variant nomenclature, you’re not alone. Due to the existence of multiple genomic sequence databases, various naming systems are in use for the rapidly growing range of SARS-CoV-2 variants of concern/interest. In a...

Making Sense of the SARS-CoV-2 Spike Mutations

by James Shore | 25th March 2021 | Coronaviruses, COVID-19, Disease insight, Disease trends, Immunoassays, New products, Research, Vaccines | 0 Comments

Through much of 2020, SARS-CoV-2 accumulated mutations at a steady, yet unspectacular rate. However, as global cases approached 100 million by the end of the year, multiple variants began to emerge. Exhibiting more considerable genomic changes, some variants have...

D614G: Putting the Mutation in Perspective

by James Shore | 10th November 2020 | Coronaviruses, COVID-19, Disease insight, Disease trends, New products, Research | 0 Comments

Since the emergence of SARS-CoV-2, scientists have speculated about the risks of mutation and what this could mean for therapeutics and vaccines. In this blog, we explore the nature viral mutation, what is known about the D614G mutant of SARS-CoV-2, and introduce our...

The Endemic Coronaviruses and What They Might Tell us About COVID-19

by James Shore | 29th July 2020 | Coronaviruses, COVID-19, Disease insight, Immunoassays, New products | 0 Comments

While less-well known than some of their counterparts, the 229E, NL63, OC43, and HKU1 human coronaviruses are a significant cause of respiratory disease worldwide. The evolutionary histories and host associations of the endemic coronaviruses also provide important...

Q&A: An Insight Into COVID-19 Serology

by James Shore | 8th July 2020 | Coronaviruses, COVID-19, Immunoassays, Research | 0 Comments

During the course of the current coronavirus pandemic, we have all been aware of the urgent need for nucleic acid testing to identify people currently infected with SARS-CoV-2. The second form of testing needed are serological immunoassays, which can identify past...

A Q&A with David Flavell of Leukaemia Busters

by James Shore | 20th May 2020 | Cancer, COVID-19, Disease insight, Research, Toxins | 0 Comments

In this blog, we speak with Dr. David Flavell about his scientific career, the legacy of Leukaemia Busters, and the recent impact that COVID-19 has had on his research.Tell me about your scientific background David. I was born in a seaside town called Southport in the...

Avoiding the Immunopathology Pitfalls of a COVID-19 Vaccine

by James Shore | 4th May 2020 | Coronaviruses, COVID-19, Disease insight, Immunoassays, Vaccines | 0 Comments

In the second of a three-part series on COVID-19 vaccines, we explore the potential challenges in stimulating safe vaccine responses and outline the role that diagnostics will play in guiding their development.Rogue Responses Antibodies play a crucial role in...

Designing for Differentiation: Why We Need Highly Specific Diagnostics for a COVID-19 Vaccine

by James Shore | 15th April 2020 | Coronaviruses, COVID-19, Immunoassays, Research, Vaccines | 0 Comments

Assessment of vaccine-induced immune responses in clinical trials will require highly specific diagnostic assays to ensure safety. This blog was originally published on Clinical Lab Manager.The Vaccine Race Vaccines are the most effective means of preventing...

An Early Look at Vaccines for COVID-19

by James Shore | 14th April 2020 | Coronaviruses, COVID-19, Vaccines | 0 Comments

In the first of a three-part series on the design, immunology and manufacture of COVID-19 vaccines, we take an early look at the major technologies under development and weigh-up the challenges these vaccines will face in reaching late-phase clinical trials.Why We...

Why We Need Antigen and Antibody Tests for COVID-19

by James Shore | 24th March 2020 | Coronaviruses, COVID-19, Disease insight, Immunoassays, New products | 0 Comments

RT-PCR is the workhorse of viral diagnosis and has been invaluable in COVID-19 case confirmation and isolation guidance. However, while fast and sensitive, PCR suffers from some inherent drawbacks that limit it to diagnosis during the acute phase of infection. To...

Novel Coronavirus Antigens Now Available

by James Shore | 11th February 2020 | Coronaviruses, Disease insight, New products | 0 Comments

The Native Antigen Company is now offering recombinant S1 and S2 glycoproteins for SARS-CoV-2 (Covid-19) in response to urgent demand. These reagents are suitable for use in basic research and the development of diagnostics and vaccines.These antigens have been...

Coronaviruses: The Next Disease X?

by James Shore | 5th November 2019 | Coronaviruses, Disease insight, New products | 0 Comments

For much of their known history, the coronaviruses were regarded as relatively benign pathogens with little potential to cause human harm. However, the emergence of SARS and MERS in recent decades has brought coronaviruses into the global spotlight. In this blog we...